help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LANES, S. F.
Right arrow Articles by WENTWORTH, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LANES, S. F.
Right arrow Articles by WENTWORTH, C. E., III

Am. J. Respir. Crit. Care Med., Volume 158, Number 3, September 1998, 857-861

Risk of Emergency Care, Hospitalization, and ICU Stays for Acute Asthma among Recipients of Salmeterol

STEPHAN F. LANES, LEE L. LANZA, and CHARLES E. WENTWORTH III

Epidemiology Resources Inc., Newton Lower Falls, Massachusetts

We used automated health insurance claims records of a New England insurer to assess the relation between salmeterol and severe nonfatal asthma. We identified 61,712 members who received a beta -agonist from January 1, 1993 to August 31, 1995, including 2,708 recipients of salmeterol. Compared with recipients of other beta -agonists, future salmeterol recipients had higher rates of asthma hospitalization and dispensings of asthma medications during the year before they received salmeterol. We selected as a comparison group 3,825 recipients of sustained-release theophylline. We defined a baseline period as the year before the start of the follow-up period, and we characterized patients according to age, sex, calendar period, presence of baseline hospitalizations for asthma, presence of chronic obstructive pulmonary disease (COPD), and baseline dispensings of asthma medications. After adjusting for baseline factors, incidence rates of severe asthma in the salmeterol group were not elevated for emergency care (rate ratio estimate [RR] = 0.69, 95% confidence intervals [CI] = 0.42, 1.11), hospitalization (RR = 1.09, 95% CI = 0.60, 1.98), or intensive care unit (ICU) stays (RR = 0.81, 95% CI = 0.25, 2.62). We conclude that salmeterol was prescribed preferentially to high-risk patients and, after adjusting for baseline risk, salmeterol recipients did not have a greater risk than theophylline recipients of severe nonfatal asthma.




This article has been cited by other articles:


Home page
 J Intensive Care MedHome page
J. Chang and Z. Mosenifar
Differentiating COPD From Asthma in Clinical Practice
J Intensive Care Med, September 1, 2007; 22(5): 300 - 309.
[Abstract] [PDF]

Home page
 ChestHome page
H. S. Nelson, S. T. Weiss, E. R. Bleecker, S. W. Yancey, P. M. Dorinsky, and the SMART Study Group
The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol
Chest, January 1, 2006; 129(1): 15 - 26.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. F. Donohue
Therapeutic Responses in Asthma and COPD: Bronchodilators
Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. F. Donohue
The Expanding Role of Long-Acting {beta}-Agonists
Chest, August 1, 2000; 118(2): 283 - 285.
[Full Text] [PDF]

Home page
 ThoraxHome page
M. Cazzola, C. F. Donner, and M. G. Matera
Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary disease
Thorax, August 1, 1999; 54(8): 730 - 736.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society